Page 2 - Nasdaq Cgem News Today

Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totalling 2,060,000 shares, a drop of 11.6% from the June 15th total of 2,330,000 shares. Based on an average daily volume of 303,400 shares, the short-interest ratio […]

Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) saw a significant drop in short interest in the month of June. As of June 30th, there was short interest totalling 2,060,000 shares, a drop of 11.6% from the June 15th total of 2,330,000 shares. Based on an average daily volume of 303,400 shares, the days-to-cover ratio […]

Cullinan Oncology (NASDAQ:CGEM – Get Rating) and Kiromic BioPharma (NASDAQ:KRBP – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Analyst Recommendations This is a breakdown of recent ratings […]

Cullinan Oncology (NASDAQ:CGEM – Get Rating) had its target price cut by HC Wainwright from $50.00 to $49.00 in a research report released on Friday morning, The Fly reports. Separately, Morgan Stanley cut their price target on Cullinan Oncology from $27.00 to $19.00 and set an overweight rating on the stock in a report on […]

HC Wainwright reaffirmed their buy rating on shares of Cullinan Oncology (NASDAQ:CGEM – Get Rating) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $50.00 price objective on the stock. Separately, Morgan Stanley dropped their price objective on Cullinan Oncology from $27.00 to $19.00 and set an overweight […]

CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial...

CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan...

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on...

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on...

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on...